Werewolf Therapeutics, Inc.
HOWL
$0.86
-$0.06-6.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -92.95% | -90.55% | -86.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -92.95% | -90.55% | -86.84% |
| Cost of Revenue | 14.33% | 19.78% | -3.47% | -3.47% | -29.28% |
| Gross Profit | -27.89% | -70.63% | -59.65% | -88.10% | -46.83% |
| SG&A Expenses | -3.96% | 3.47% | 10.16% | 15.78% | 15.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.89% | 7.97% | 22.55% | 24.87% | 4.74% |
| Operating Income | -8.15% | -25.15% | -63.78% | -81.70% | -62.59% |
| Income Before Tax | -17.26% | -36.13% | -74.15% | -88.70% | -66.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.26% | -36.13% | -74.15% | -88.70% | -66.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.26% | -36.13% | -74.15% | -88.70% | -66.56% |
| EBIT | -8.15% | -25.15% | -63.78% | -81.70% | -62.59% |
| EBITDA | -8.63% | -26.13% | -66.47% | -85.29% | -65.07% |
| EPS Basic | -8.31% | -22.09% | -50.02% | -55.05% | -34.88% |
| Normalized Basic EPS | -9.25% | -23.27% | -48.89% | -53.86% | -33.75% |
| EPS Diluted | -6.42% | -19.52% | -52.68% | -57.83% | -37.51% |
| Normalized Diluted EPS | -9.59% | -23.70% | -48.47% | -53.42% | -33.33% |
| Average Basic Shares Outstanding | 8.88% | 13.12% | 18.17% | 21.57% | 20.97% |
| Average Diluted Shares Outstanding | 8.54% | 12.74% | 18.52% | 21.93% | 21.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |